- Home
- TRUG vs XBIO Comparison
TRUG vs XBIO Comparison
Compare TRUG & XBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRUG
- XBIO
- Stock Information
- Founded
- TRUG 1983
- XBIO N/A
- Country
- TRUG United States
- XBIO United States
- Employees
- TRUG N/A
- XBIO N/A
- Industry
- TRUG
- XBIO Biotechnology: Pharmaceutical Preparations
- Sector
- TRUG
- XBIO Health Care
- Exchange
- TRUG NYSE
- XBIO Nasdaq
- Market Cap
- TRUG 7.4M
- XBIO 6.3M
- IPO Year
- TRUG N/A
- XBIO N/A
- Fundamental
- Price
- TRUG $0.37
- XBIO $4.06
- Analyst Decision
- TRUG
- XBIO Hold
- Analyst Count
- TRUG 0
- XBIO 1
- Target Price
- TRUG N/A
- XBIO N/A
- AVG Volume (30 Days)
- TRUG 11.5M
- XBIO 22.9K
- Earning Date
- TRUG 02-12-2025
- XBIO 11-12-2024
- Dividend Yield
- TRUG N/A
- XBIO N/A
- EPS Growth
- TRUG N/A
- XBIO N/A
- EPS
- TRUG N/A
- XBIO N/A
- Revenue
- TRUG $21,917,131.00
- XBIO $2,523,427.00
- Revenue This Year
- TRUG N/A
- XBIO N/A
- Revenue Next Year
- TRUG N/A
- XBIO N/A
- P/E Ratio
- TRUG N/A
- XBIO N/A
- Revenue Growth
- TRUG 7.68
- XBIO 7.15
- 52 Week Low
- TRUG $0.35
- XBIO $2.78
- 52 Week High
- TRUG $11.82
- XBIO $5.20
- Technical
- Relative Strength Index (RSI)
- TRUG 39.73
- XBIO 47.20
- Support Level
- TRUG $0.42
- XBIO $3.92
- Resistance Level
- TRUG $0.92
- XBIO $4.27
- Average True Range (ATR)
- TRUG 0.11
- XBIO 0.27
- MACD
- TRUG 0.00
- XBIO -0.05
- Stochastic Oscillator
- TRUG 3.98
- XBIO 19.09
About TRUG TRUGOLF HOLDINGS INC
TruGolf Holdings Inc is a indoor golf gaming solutions company. It has built video games ("Links"), innovative hardware solutions, and an all-new e-sports platform to connect golfers around the world with E6 CONNECT.
About XBIO Xenetic Biosciences Inc.
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immune-oncology technologies addressing cancers. The company is also engaged in progressing XCART, a personalized CAR T platform technology. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which have been implicated in cancer progression and resistance to cancer treatments. The company also has oncology therapeutic investigational drug candidate XBIO-101 for the treatment of progestin-resistant endometrial cancer.